Bacterial endotoxin in research-supply peptide presentations
What is known about bacterial endotoxin content in peptides supplied for research and injected in practice?
§1Abstract
§1.1Review question
What is known about bacterial endotoxin content in peptides supplied for research and injected in practice?
§1.2PICO frame
Table 1. The registered PICO frame. Any change made after protocol registration is recorded in the amendment log at §5 and is identified there as post hoc.
| Element | As registered |
|---|---|
| Population | Lyophilised peptide presentations supplied for research. |
| Intervention | Not applicable. |
| Comparator | The pharmacopoeial endotoxin limit for a parenteral of the corresponding dose. |
| Outcomes | Endotoxin content in endotoxin units per vial and per kilogram of body weight at the doses used. |
§1.3Method in brief
A review of analytical and quality evidence for a compound or class as supplied, rather than of clinical effect. The protocol was registered with the Institute's secretariat before the search was executed. The search was run on 14 April 2025 across 8 sources and is reproduced in full at §2. Screening, extraction and certainty assessment were performed independently by two members of the secretariat with disagreement resolved by a third.[1,2]
§1.4Conclusion
Low certainty evidence bears on this question because almost no data exist. Endotoxin was reported on none of the certificates in the Institute’s sampled set. The Institute records that endotoxin is the quality attribute least often measured and among those most likely to matter for an injected product, that a bacterially expressed recombinant protein carries a materially higher prior probability of endotoxin contamination than a solid-phase synthetic peptide, and that a purity figure carries no information about it whatsoever.
The conclusion rests on 24 contributing studies, listed with their extracted data at §3 and summarised outcome by outcome at §4.
§1.5Limitations
§1.6Consultation
This review was released for public comment before ratification. Draft synthesis: Bacterial endotoxin in research-supply peptide presentations received 2 submissions. Amendments arising are recorded in the amendment log and are traceable to a numbered submission.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- United States Pharmacopeial Convention. General Chapter ⟨85⟩ Bacterial Endotoxins Test. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.